SARS-CoV-2 Variants and Vaccines
New England Journal of Medicine2021Vol. 385(2), pp. 179–186
Citations Over TimeTop 1% of 2021 papers
Philip R. Krause, Thomas R. Fleming, Ira M. Longini, Richard Peto, Sylvie Briand, Dominique Heymann, Valerie Beral, Matthew D. Snape, Helen Rees, Alba-Maria Ropero, Ran D. Balicer, Jakob P. Cramer, César Muñoz‐Fontela, Marion F. Gruber, Rogerio Gaspar, Jerome Amir Singh, Kanta Subbarao, Maria D. Van Kerkhove, Soumya Swaminathan, Michael J. Ryan, Ana‐Maria Henao‐Restrepo
Abstract
Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19). Moreover, if some variants of concern have increased transmissibility or virulence, the importance of efficient public health measures and vaccination programs will increase. The global response must be both timely and science based.
Related Papers
- → A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa(2022)11 cited
- → Mutator Natural Escherichia coli Isolates Have an Unusual Virulence Phenotype(2001)51 cited
- → Virulence evolution(2021)4 cited
- → Effect of viscous damping on power transmissibility for the vibration isolation of building services equipment(2006)12 cited
- → Discontinuous Variation in the Virulence of Bact. aertrycke Mutton(1928)10 cited